Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
about
PI3K/Akt/mTOR inhibitors in breast cancerThe fate of chemoresistance in triple negative breast cancer (TNBC)Triple negative breast cancer: looking for the missing link between biology and treatmentsBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesEverolimus in the Treatment of Metastatic Breast CancerTaxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data.Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialPatient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsTriple-negative breast cancer: new perspectives for targeted therapies.SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancerTriple-negative breast cancer: an update on neoadjuvant clinical trials.Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.Trends of triple negative breast cancer research (2007-2015): A bibliometric study.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Clinical development of mTOR inhibitors in breast cancer.Therapies for triple negative breast cancer.New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway.The therapeutic potential of mTOR inhibitors in breast cancer.Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.Safety of mTOR inhibitors in breast cancer.Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.Signaling pathway profiling using reverse-phase protein array and its clinical applications.Targeting the mTOR pathway in breast cancer.ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.Therapeutic landscape in mutational triple negative breast cancer
P2860
Q26771394-6F04551B-F455-4FCC-AF8D-DB327FBF9930Q26775232-91F17154-3B03-43C0-8AB9-D20B1C604C7BQ26783122-B9C8B244-8B28-460F-AB44-349DF5935ACFQ26783705-58C7EEC1-92F3-41AD-BC5E-A7FCAB5ED8C5Q26784920-C1E06F26-C60B-45A0-AFB5-89D561FAAFC0Q30251429-BC8CA89F-2436-4A73-A9BD-6EA2F962FB5EQ30583249-9665A957-FED4-45E4-8467-C42A5AD821A4Q31134060-2821AAF8-CFD7-4DBA-9831-A6724B897466Q33434092-E20EF0A5-D22D-400B-B4B9-2D603E1003EFQ33739184-2DC3FF47-C407-46E3-939C-251D30005A79Q33887682-78A51EED-9FB4-4141-8E11-99B5807FACFDQ34646376-F984905F-F243-4B12-8266-BC4C6DFBF92FQ35001758-4572C0AB-A015-4DB2-8C50-5336051931AEQ35127249-569AC423-74D6-458F-B615-FC61C8225065Q35725961-F417E43C-D5BD-418D-93C3-881053371636Q37105085-AD85B483-9B46-4E92-A2F8-4AA0BD82B2F6Q37433105-96B1E67B-A1DD-4F32-AF46-675C0BC70195Q37645090-764FE16E-5F64-4F74-BF80-4768F4F76B96Q37690076-94EAE829-AE37-4FC2-BD84-190E11395586Q38424397-3E6CFAA5-C4D0-4AF5-8EA6-0F9D5552E09BQ38604713-665C458A-83A1-44D2-9BC2-70307B44DC99Q38802412-4F81D12E-0286-4D78-8DE3-9962D9064DE0Q38825945-DE4E427F-7C85-4BB9-85A7-4519D0F4430AQ38841039-19E1A454-F083-4AB0-BFD6-E0B5524FB6FFQ38882776-FD41D689-09B6-428F-908A-46F265641B41Q39377837-C9A32241-CB4E-41A6-B0FD-FA2F48B7A20EQ39390640-44D4B4BB-E4A2-4BC3-B9D1-2F81069773F8Q41674321-D85A09BD-AF05-4101-82E6-BED959838D46Q47121796-E28637D7-FEAB-417B-B20F-13DBA7475133Q48551091-0774F3CE-4E44-4237-9E1F-AECDFCA2EE5CQ54965602-6348EA95-1FF9-416E-B07E-3BBBCC947DBCQ55428234-67118859-1AF2-4677-93C2-28AD5865295CQ57109569-185D0B2A-4CED-4805-8DB7-4693746F2082
P2860
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Open-label randomized clinical ...... eptor-negative breast cancer†.
@ast
Open-label randomized clinical ...... eptor-negative breast cancer†.
@en
type
label
Open-label randomized clinical ...... eptor-negative breast cancer†.
@ast
Open-label randomized clinical ...... eptor-negative breast cancer†.
@en
prefLabel
Open-label randomized clinical ...... eptor-negative breast cancer†.
@ast
Open-label randomized clinical ...... eptor-negative breast cancer†.
@en
P2093
P2860
P356
P1433
P1476
Open-label randomized clinical ...... ceptor-negative breast cancer†
@en
P2093
A Akcakanat
A M Brewster
A M Gonzalez-Angulo
D Crawford
F Meric-Bernstam
G N Hortobagyi
P2860
P304
P356
10.1093/ANNONC/MDU124
P577
2014-03-24T00:00:00Z